American Society of Hirudotherapy

Ornatin

RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Ornatin5.5 kDa
Molecular weight (kilodaltons) of Ornatin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Ornatin's in vitro antagonism of platelet GP IIb/IIIa does not establish clinical efficacy. No FDA-approved derivative exists. Mechanism is preclinical/biochemical only.

Molecular Profile

Category
Antiplatelet
Evidence tier
Preclinical
Molecular weight
5,500 Da
Source species
Placobdella ornata
Discovered
1991 · Mazur et al.

Biological Targets

  • → platelet integrin αIIbβ3 (GP IIb/IIIa)

Key Citations

  1. Mazur P et al. (1991), J Biol Chem

External Resources

    Related Antiplatelet Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.